室腔动心术的导管切除:目前的情况和未来的前景
Naoya Kataoka1, Teruhiko Imamura1
1Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Journal of clinical medicine
|November 27, 2024
概括
静心性心力衰竭中心室动脉冲动 (VT) 的导管切除具有挑战性,因为向和深层病变的形成存在困难. 新兴技术和新的废弃源旨在提高疗效并减少痕相关静脉瘤的复发.
科学领域:
- 心脏病学 心脏病学
- 电力生理学 电力生理学
- 医疗技术 医疗技术 医学技术
背景情况:
- 静心性心力衰竭中腹腔动心 (VT) 的导管切除是一种关键的非药物治疗方法.
- 目前的证据表明静脉管切除可以降低心脏病死亡率,但由于目标识别的非标准化策略和挑战,这些证据并不确.
- 像电压映射这样的现有映射技术在识别深层目标和区分活跃组织与痕方面存在局限性.
研究的目的:
- 通过使用单极潜力评估再极化异质性,审查用于识别VT废除目标的新兴技术.
- 探索新的废除来源,以创造更深,更持久的病变,以克服传统射频废除的局限性.
- 增强对优化痕相关VT程序结果的创新策略的理解.
主要方法:
- 综述当前关于静脉通道切除在心力衰竭中进行静脉通道切除的文献.
- 分析功能基板映射的进展和单极潜力分析,用于识别VT峡谷.
- 探索新的废弃技术,包括脉冲场废弃,双极废弃和超低温冷废弃.
主要成果:
- 利用单极潜力的新兴技术可以评估再极化异质性并识别VT峡谷.
- 与射频废除相比,新的废除来源在创造更深,更持久的病变方面表现有希望.
- 改进的目标识别和病变创建旨在减少静脉瘤的复发并提高治疗效率.
结论:
- 绘图和切除技术的进步对于改善痕相关静脉瘤导管切除的结果至关重要.
- 预计利用单极潜力和新型废弃源的创新策略将优化程序的成功.
- 需要进一步的研究和标准化,以确定静脉管切除作为减少心力衰竭患者心脏病死亡率的最终治疗方法.
相关概念视频
Disturbances in Heart Rhythm
907
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
907
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
780
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
780


